Viking Therapeutics, Inc.
VKTX
$31.32
-$0.40-1.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -158.33M | -157.66M | -90.79M | -65.56M | -45.63M |
| Total Depreciation and Amortization | 85.00K | 94.00K | 114.00K | 112.00K | 111.00K |
| Total Amortization of Deferred Charges | -- | 0.00 | 8.00K | 24.00K | 24.00K |
| Total Other Non-Cash Items | 9.05M | 6.80M | 5.31M | 11.16M | 8.23M |
| Change in Net Operating Assets | 35.22M | 65.48M | -8.64M | 7.20M | -15.06M |
| Cash from Operations | -113.98M | -85.29M | -94.00M | -47.06M | -52.33M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 54.19M | 75.61M | 160.03M | 42.51M | 63.25M |
| Cash from Investing | 54.19M | 75.61M | 160.03M | 42.51M | 63.25M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.08M | 75.10M | 480.00K | 507.00K | 349.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.08M | 75.10M | 480.00K | 507.00K | 349.00K |
| Foreign Exchange rate Adjustments | 16.00K | 9.00K | -6.00K | -12.00K | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -47.69M | 65.43M | 66.50M | -4.06M | 11.26M |